Research and Development

Showing 15 posts of 9612 posts found.

top_ten

Top ten stories in the pharmaceutical industry this week

August 26, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharmafile, top 10

If this week left you feeling with a sense of déjà vu, you could certainly be forgiven. With US politicians …
mylan_building

Mylan announces immediate plans to cut price of EpiPen

August 25, 2016 Medical Communications, Research and Development Mylan, clinton, epipen, increase

Subject to intense pressure over the last few days, Mylan has made an attempt to avoid becoming “another Valeant” by …
chemo-web

Boost for Clovis as FDA grants priority review for rucaparib in ovarian cancer

August 25, 2016 Research and Development, Sales and Marketing FDA, clovis, ovarian cancer, rucaparib

Clovis Oncology has announced that the US Food and Drug Administration has accepted its new drug application for rucaparib, and …
novartis_malaria_researcher

Positive Phase III results for Novartis MS drug

August 25, 2016 Research and Development Novartis, multiple sclerosis, phase III

Novartis has announced positive Phase III results for its EXPAND study, an evaluation of the efficacy and safety of orally-administered, …
teva_copy

Teva loses patent protection on lucrative MS treatment

August 25, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, Mylan, Teva, multiple sclerosis

Teva’s stock plunged 3% after a US agency ruled that two of its patents related to multiple sclerosis drug Copaxone …
amgen_flag

FDA says no to Amgen’s Parsabiv

August 25, 2016 Research and Development, Sales and Marketing Amgen, FDA, par

Amgen has announced that the US Food and Drug Administration (FDA) has issued a complete response letter rejecting Parsabiv (etelcalcetide) …
fdaoutsideweb

Medical device user fees to increase 68% for 2018 to 2022

August 25, 2016 Research and Development, Sales and Marketing FDA, Medical device

The Food and Drug Administration has reached an agreement with the medical device industry and laboratory community on proposed recommendations …
mylan_plus_hero_720x510

Mylan latest target of US anger on drug pricing with EpiPen price increase

August 24, 2016 Research and Development, Sales and Marketing Mylan, US, congress, controversy, epipen, price gouging, price increase

The US congress is again subjecting the pharmaceutical industry to heavy scrutiny over drug pricing policies with Mylan its latest …

NICE approves lung cancer and leukaemia treatments

August 24, 2016 Research and Development, Sales and Marketing Alimta, CDF, NICE, bosulif, bosutinib, pemetrexed

The National Institute for Health and Care Excellence (NICE) has issued its approval of two drugs for routine use on …
pfizer_sky

Pfizer to acquire AstraZeneca’s anti-infective business for $550 million upfront

August 24, 2016 Research and Development, Sales and Marketing AstraZeneca, Pfizer, Zavicefta, anti-infective

Pfizer has announced that it is to acquire AstraZeneca’s small molecule anti-infective business in a deal potentially worth up to …
eylea-product-box-md

NICE recommends Eylea as first-line treatment for sight threatening condition

August 24, 2016 Research and Development, Sales and Marketing Bayer, Eylea, NHS, NICE, first-line treatment

Bayer has announced that the National Institute for Health and Care Excellence (NICE) has recommended Eylea (aflibercept) as a cost-effective …
1397501171305

AbbVie’s leukaemia drug granted positive opinion by MHRA through EAMS

August 23, 2016 Research and Development, Sales and Marketing

AbbVie’s investigational treatment for chronic lymphocytic leukaemia (CLL) venetoclax has been granted a positive scientific opinion by the Medicines and …
t_cell_grey_killing_tumour_cell_yellow

Foundation Medicine adds new immunotherapy features to its gene profiling products

August 23, 2016 Manufacturing and Production, Research and Development FoundationOne, oncology, tumour

Foundation Medicine hopes to enhance oncologist insight into potential immunotherapy responses with the addition of new clinical markers to its …
casebia

Bayer’s CRISPR venture opens for business in biotech hub

August 23, 2016 Manufacturing and Production, Research and Development Bayer, casebia, crispr, gene editing, gene-editing

Bayer and CRISPR Therapeutics have joined together to launch Casebia Therapeutics and have chosen Cambridge, Massachusetts, as its base to …
paul_herendeen

Valeant appoints new executive VP of finance and CFO

August 22, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Valeant, appointment

Valeant has announced the appointment of Paul S. Herendeen as executive vice president, who will also take over as chief …
The Gateway to Local Adoption Series

Latest content